# The Intravitreal Autologous Platelet Concentrate Injection as an Adjunct of Vitrectomy for the Treatment of Refractory Macular Holes

> **NCT02081170** · NA · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 16 (estimated)

## Conditions studied

- Macular Hole With High Myopia (Spherical Equivalent ≤ -6.0 Diopters) or,
- Large Size Macular Hole (Diameter > 600 Microns) or
- Recurred or Failed Macular Hole From Previous Surgery
- or Chronic Macular Hole (Symptom Duration > 6 Months)

## Interventions

- **PROCEDURE:** Autologous platelet concentrate

## Key facts

- **NCT ID:** NCT02081170
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2014-12
- **Final completion:** —
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2014-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02081170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02081170, "The Intravitreal Autologous Platelet Concentrate Injection as an Adjunct of Vitrectomy for the Treatment of Refractory Macular Holes". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02081170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*